JPRN-UMIN000001226
Recruiting
Phase 2
Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) - Phase II trial using imatinib combined with chemotherapy for Ph+A
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- ewly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
- Sponsor
- Japan Adult Leukemia Study Group
- Enrollment
- 66
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Infectious disease of Grade 4 2\) Positive HIVAb or HBsAg 3\) Active cancer other than ALL 4\) Female patients who are pregnant or breast\-feeding 5\) Reject by responsible physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)Acute Lymphoblastic LeukemiaNCT00130195Japan Adult Leukemia Study Group100
Active, not recruiting
Phase 1
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
Active, not recruiting
Not Applicable
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240
Recruiting
Phase 2
A randomised phase II trial of imatinib alternating with;regorafenib compared to imatinib alone for the first line ;treatment of advanced gastrointestinal stromal tumour (GIST)gastrointestinal stromal tumourGIST10072990NL-OMON56311European Organisation for Research in Treatment of Cancer (EORTC)18
Active, not recruiting
Phase 1
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)EUCTR2015-001298-42-FREuropean Organisation for Research and Treatment of Cancer240